PTO/\$B/26 (09-04) Approved for use through 07/31/2006. OMB 05/3-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

luction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. Docket Number (Optional)

ERMINAL DISCLAIMER TO OBVI	ATE A DOUBLE DATENTING
EBBINAL DISCLAIMER TO CIRVI	ALE A DUBBLE PATENTING
EKMINAL DISCENIEN 10 001.	ALC NO CODE : The control of the con
DE JECTION OVER A "	DDIND" DATENI

446.016-DIV

In re Application of: Peyman, et al.

Application No.:

10/808,496

Filed:

March 24, 2004

For:

NAPHTHYRIDINE ... THEM

equal owners

Aventis Pharma Deutschland GmbH

percent interest in the instant application hereby disclaims, Genentech Inc. The owner', except as provided below, the terminal part of the statutory term of any patent granted on the instant application which would extend beyond the expiration date of the full statutory term prior patent No. 6, 743, 800 as the term of said prior patent is defined in 35 U.S.C. 154 and 173, and as the term of said prior patent is presently shortened by any terminal disclaimer. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of the term of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of the prior patent, "as the term of said prior patent is presently shortened by any terminal disclaimer," in the event that said prior patent later:

expires for failure to pay a maintenance fee;

is held unenforceable;

is found invalid by a court of competent jurisdiction;

is statutority disclaimed in whole or terminally disclaimed under 37 CFR 1.321;

has all claims canceled by a reexamination certificate;

is reissued: or

is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaims

Check either box 1 or 2 below, if appropriate.

For submissions on behalf of a business/organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the business/organization.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

2. X The undersigned is an attorney or agent of record. Reg. No. 19,683

Climbes A Missel

Aug. 4, 2005

Charles A. Muserlian

Typed or printed name

212 302 8989

Telephone Number

X Terminal disclaimer fee under 37 CFR 1.20(d) included.

WARNING: information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

\*Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner). Form PTO/SB/96 may be used for making this certification. See MPEP § 324.

This collection of information is required by 37 CFR 1.321. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any @mments including gathering, preparing, and submitting the complete drip complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U:S. Patent and Tredemark Office, U.S. Department of Continerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450; Alexandria, VA 22313-1450. 022275

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

08/09/2005 EFLORES 00000059 10808496

01 FC:1999

110.00 OP

38/17/2005 TBARDEN 00000001